改良VAD方案治疗多发性骨髓瘤临床疗效观察  

The Observation of Clinical Efficacy of Modified VAD Regimen in the Treatment of Multiple Myeloma

作　　者：万鼎铭[1] 王岩[1] 程远东[1] 孙慧[1] 孙玲[1] 谢新生[1] 刘少君[1] 张素平[1] 邵运丽[1] 

机构地区：[1]郑州大学第一附属医院血液科,河南郑州450052

出　　处：《肿瘤基础与临床》2011年第1期15-16,共2页journal of basic and clinical oncology

摘　　要：目的观察改良VAD方案治疗初治多发性骨髓瘤的临床疗效及毒副反应。方法采用改良VAD方案和标准VAD方案治疗初治多发性骨髓瘤,并分别观察两者的疗效和毒副反应。结果改良VAD方案有效率与标准VAD方案比较差异无统计学意义(P>0.05);改良VAD方案的毒副反应发生率明显低于标准VAD方案(P<0.05)。结论改良的VAD方案治疗多发性骨髓瘤安全有效,有可能替代标准VAD方案。Objective To observe the clinical efficacy and toxicities of modified VAD regimen in the treatment of initial multiple myeloma. Methods The patients with initial multiple myeloma were treated with modified VAD regimen or standard VAD regimen, the efficacy and toxicities were respectively evaluated in the two groups. Results There was no significant difference between the efficacy of modified VAD regimen and standard regimen（P 〉 0.05 ）, but the modified VAD regimen could reduce the toxicities （ P 〈 0.05 ）. Conclusion Modified VAD regimen is safe and effective, may replace the standard VAD regimen.

关 键 词：多发性骨髓瘤 改良VAD方案 地塞米松 

分 类 号：R733.3[医药卫生—肿瘤]